SCHEMBL4377232

SCHEMBL4377232

O=C(CSc1ccc(F)cc1)N1CCN(C2CCCCC2)CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
PKM P14618 4/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
GAA P10253 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
KDM4E B2RXH2 3/20 0.50
KMT2A Q03164 2/20 0.50
USP2 O75604 1/20 0.50
TSHR P16473 1/20 0.50
UBE2N P61088 1/20 0.50
LMNA P02545 1/20 0.50
HRH3 Q9Y5N1 3/20 0.48
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4377416 0.99 PKM (0.55) ALDH1A1PKML3MBTL1GAASMN1; SMN2
SCHEMBL2833292 0.88 L3MBTL1 (0.58) ALDH1A1PKML3MBTL1GAASMN1; SMN2
SCHEMBL9527356 0.83 RAB9A (0.69) ALDH1A1PKML3MBTL1GAASMN1; SMN2
SCHEMBL4380926 0.81 KDM4E (0.60) ALDH1A1L3MBTL1GAASMN1; SMN2RAB9A
SCHEMBL4378548 0.81 USP2 (0.52) ALDH1A1L3MBTL1SMN1; SMN2NPC1KDM4E
SCHEMBL4378474 0.80 KDM4E (0.61) ALDH1A1L3MBTL1GAASMN1; SMN2RAB9A
SCHEMBL4377596 0.80 USP2 (0.51) ALDH1A1SMN1; SMN2NPC1KDM4EKMT2A
SCHEMBL4378521 0.77 KDM4E (0.71) ALDH1A1GAASMN1; SMN2RAB9AKDM4E
SCHEMBL4378928 0.75 KDM4E (0.73) ALDH1A1GAASMN1; SMN2RAB9AKDM4E
SCHEMBL3776110 0.74 MEN1 (0.61) ALDH1A1SMN1; SMN2NPC1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 ALDH1A1 1907/4885PKM 2476/4885L3MBTL1 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.